Bausch Health Companies Inc. (BHC) Stock
BHC has an Alpha Score of 37 out of 100 (weak), computed on Nov 1, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 3 trades in BHC since 2020: 2 purchases and 1 sale, most recently Susie Lee (sale, Aug 27, 2020). 7 of the hedge funds AlphaScala tracks reported BHC in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Paulson & Co's at $361.15M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 21.1 and its net margin -10.1% (key statistics as of Nov 1, 2026).
What is BHC's Alpha Score?
How it works →Alpha Score of 37 reflects weak overall profile with moderate momentum, weak value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Bausch Health Companies Inc. (BHC)?
Most recent: Susie Lee (sale, Aug 27, 2020); records start Jan 6, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Susie Lee D-NV · House | 2020-08-27 | sale | $1k – $15k |
| Susie Lee D-NV · House | 2020-02-24 | purchase | $1k – $15k |
| Susie Lee D-NV · House | 2020-01-06 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026.
See all BHC political trades →Which hedge funds own BHC?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Paulson & Co John Paulson | 73.26M | $361.15M | n/a |
| D.E. Shaw David Shaw | 2.69M | $13.26M | +333% |
| Point72 Steve Cohen | 2.24M | $11.02M | +66% |
| Renaissance Technologies Jim Simons (founder) | 1.32M | $6.53M | -16% |
| Citadel Ken Griffin | 1.11M | $5.45M | +21% |
| Millennium Management Israel Englander | 1.10M | $5.39M | +151% |
| Bridgewater Associates Ray Dalio | 866K | $4.27M | +29% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Bausch Health Companies Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Lenar Aimee J. | President, US Pharma | SELL | 36.8K | $259K |
SEC Form 4 filings as of Oct 30, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →What are BHC's key statistics?
Key statistics as of Nov 1, 2026
How does BHC's valuation compare with the Healthcare sector?
| Metric | BHC | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 21.1 | 27.2 | 99 |
| Net margin | -10.12% | 4.85% | 143 |
| Return on equity | -96.76% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
BHC price chart
Powered by TradingViewWhat does Bausch Health Companies Inc. do?
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.